PHARMACEUTICAL 2024

ELI Lilly Co
Rank 173 of 309



PHARMACEUTICAL 2024

ELI Lilly Co
Rank 173 of 309

The relative strengths and weaknesses of ELI Lilly Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI Lilly Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 48% points.The greatest weakness of ELI Lilly Co is the variable Liabilities, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 187%, being 26% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	25,727,000
Cost of Goods Sold	7,082,200
Intangible Assets	11,846,300
Liabilities, Current	27,293,200
Liabilities, Non-Current	25,849,400
Other Assets	13,519,400
Other Compr. Net Income	-482,400
Other Expenses	1,285,200
Other Liabilities	0
Other Net Income	0
Other Revenues	34,124,100
Property and Equipment	12,913,600
Research and Development	13,113,200
Selling, General and Administrative Expense	7,403,100

Output Variable	Value in 1000 USD
Assets	64,006,300
Liabilities	53,142,600
Expenses	28,883,700
Revenues	34,124,100
Stockholders Equity	10,863,700
Net Income	5,240,400
Comprehensive Net Income	4,999,200
BaseVar	90,319,550
ECR before LimitedLiability	49%
Economic Capital Ratio	187%